Index
5-flucytosine
β-lactam
abacavir
abacavir/lamivudine
acetazolamide (Diamox®)
Acinetobacter
Actinomyces
acyclovir (ACV)
acyclovir-resistant HSV, management of
adefovir
adenovirus
adult transplant recipients
antifungal agents in
antiviral agents for
adult vaccination schedule
after allogeneic stem cell transplant
live vaccines
non-live vaccines
travel or as needed
after solid organ transplant
live vaccines
non-live vaccines
vaccinations prior to travel
Aeromonas hydrophilia
albendazole
aldara
alemtuzumab (Campath)
infectious risks associated with
duration of effect
mechanism
allogeneic hematopoietic stem cell transplant recipients
antimicrobial prophylaxis regimen for
allogeneic stem cell transplant, adult vaccination schedule after
live vaccines
non-live vaccines
travel or as needed
alprazolam
altitude illness prophylaxis
amantadine (Symmetrel)
amantadine
amebiasis
colonization
extraintestinal
intestinal
amikacin (AMIK)
aminoglycoside
aminoglycoside-resistant infection
aminoglycoside therapy
amoxicillin
amoxicillin-clavulanate
amphotericin
amphotericin B
amphotericin B cholesteryl sulfate complex (ABCD)
amphotericin B deoxycholate (AmB-D)
amphotericin B lipid complex (ABLC)
amphotericin B liposomal (L-AmB)
ampicillin
ampicillin-sulbactam
anaerobes
anaerobic bacilli
anidulafungin
anthrax vaccine
anti-arrhythmics
anti-Aspergillus prophylaxis, usage of
antifungal agents
in adult transplant recipients
for pediatric transplant recipients
anti-HBc-positive recipient, hepatitis B management in
anti-HBs-negative recipient, hepatitis B management in
anti-HBs-positive recipient, hepatitis B management in
anti-metabolites
antimicrobial agents and common immunosuppressive drugs
drug interactions between
antibacterial agents
antifungals
antivirals
highly active antiretroviral therapy (HAART)
anti-pseudomonal beta-lactam
anti-thymocyte globulin (ATG)
infections associated with
duration of effect
mechanism of action
anti-thymocyte globulin (rabbit) (Thymoglobulin®)
infections associated with
antiviral agents
for adult transplant recipients
for pediatric transplant recipients
artemether/lumefantrine (Coartem®)
aspergillosis
Aspergillus
Aspergillus flavus
Aspergillus fumigatus
Aspergillus niger
Aspergillus terreus
asymptomatic bacteriuria
atazanavir
atovaquone
atovaquone/proguanil (Malarone®)
autologous hematopoietic stem cell transplant recipients
antimicrobial prophylaxis regimen for
azathioprine (AZA)
azidothymidine (AZT)
azithromycin (AZ)
azole antifungals
azoles
use of
aztreonam
Babesia
babesiosis
bacillus Calmette-Guérin (BCG) vaccine
bacteremia
in donor
bacterial coliforms
bacterial colonization
bacterial infection
after hematopoietic stem cell transplant
after organ transplant
alemtuzumab (Campath®), infections associated with
anti-thymocyte globulin (ATG), infections associated with
IL-2R antagonist, infections associated with
rituximab, infections associated with
bacterial meningitis
in donor
bacterial meningitis, acute
bacterial pneumonia
bacterial prophylaxis regimen
for allogeneic hematopoietic stem cell transplant recipients
for autologous hematopoietic stem cell transplant recipients
bacterial tracheobronchitis
Bacteroides spp.
Balamuthia
Balamuthia meningitis
balantidiasis
Balantidium coli
BAL galactomannan
baraclude
Bartonella
basiliximab (Simulect®)
IL-2R Antagonist
B-cell engraftment
belladonna
benznidazole
benzodiazepines
benztropine
beta-lactam
betalactamase inhibitor
bile leak
biloma, infected
BK polyomavirus (BKV)
alemtuzumab (Campath®)
anti-thymocyte globulin (ATG), infections associated with
BKV viremia, treatment of
IL-2R antagonist
kidney transplant recipients, replication in
non-kidney solid organ transplant recipients, replication in
rituximab
BKV replication and PyVAN in non-kidney solid organ transplant (SOT) recipients
Blastomyces
Blastomyces dermatitidis
blastomycoses
bloodstream infection, gut-associated
bocavirus infection, prevention and treatment of
bronchiolitis obliterans syndrome
bronchoalveolar lavage (BAL)
bacterial culture, presence of
bronchodilator
Brucella
Burkholderia cenocepacia
Burkholderia cepacia
CF lung transplant, infection in
Burkholderia cepacia selective agar (BCSA)
calcineurin inhibitors (CNIs)
calcium-channel blocker (CCB)
Campylobacter
Candida
Candida albicans
Candida glabrata
Candida krusei
candidal meningitis
Candida parapsilosis
candidasis
Candida spp.
Candida tropicalis
candidiasis
capreomycin
carbamazepine
carbapenem
caspofungin
cefazolin
cefepime
cefixime
cefotaxime
cefoxitin
cefpodoxime
ceftazidime
ceftriaxone
cefuroxime axetil
cellulitis
cepacia
cephalosporin
cetirimide E-test
Chagas disease
donor with
chickenpox
management of
Chlamydia pneumonia
Chlamydia sp.
chloroquine
cholangitis
cidofovir
ciprofloxacin
cisapride
clarithromycin (CLARI)
clindamycin
Clostridium difficile
colitis, after transplantation
mild to moderate
relapsing
severe/toxic megacolon
Clostridium spp.
clotrimazole
CMV antibody
CMV CNS disease
CMVIg (Cytogam®)
CMV pneumonia
CMV pneumonitis
CMV retinitis
CMV syndrome
CNS/disseminated microsporidiosis
coagulase-negative staphylococci
Coccidioides
Coccidioides antibody
Coccidioides immitis
Coccidioides infection
colistin
colitis
condylox
coronavirus infection, prevention and treatment of
corticosteroids
Coxiella burnetii serology
cryptococcal meningitis
cryptococcosis
Cryptococcus
Cryptococcus antigen
cryptosporidiosis
Cryptosporidium
Cryptosporidium antigen
Cryptosporidium muris
Cryptosporidium parvum
cyclodextrin
cycloserine
Cyclospora sp.
cyclosporiasis
cyclosporine (CsA)
Cyclosporine (CsA) Modified (Neoral®, Gengraf®)
cytomegalovirus (CMV)
alemtuzumab (Campath®)
anti-thymocyte globulin (ATG), infections associated with
donors and recipients, pediatric CMV serology interpretation in
ganciclovir (GCV)-resistant CMV infection and disease management, algorithm for
IL-2R antagonist
organ transplant recipients, algorithm for pre-emptive therapy in
prevention in solid organ transplant (SOT) recipients
rituximab
solid organ transplant (SOT) recipients
prevention in
treatment
cytovene
daclizumab (Zenapax)
IL-2R antagonist
dalfopristin
dapsone
daptomycin
darunavir
delavirdine
deoxycholate
dexamethasone
diptheria, tetanus and acellular pertussis (DTap) vaccine
disseminated disease, management of
documented infections, donor with
dolfetilide
donor-derived infections
donor scenarios, management of
transmission of infections, from donor to recipient
donor tuberculosis
potential scenarios and management
DOT therapy
doxycycline
echinocandin
efavirenz
empiric antifungal therapy, in febrile neutropenia
empiric antimicrobial therapy, in febrile neutropenia
empyema
emtricitabine
encephalitis
engraftment, factors delaying
Entamoeba histolytica
entecavir
enteric gram-negative bacilli
enteritis
Enterobacter
enterobacteriaceae
enterococci
Enterococcus
Enterococcus faecium
Enterococcus spp.
Enterocytozoon bieneusi
enteroviruses infections, prevention and treatment of
epivir
Epstein–Barr virus (EBV)
and post-transplant lymphoproliferative disorders
Epstein–Barr virus (EBV) antibody
ertapenem
erythromycin
Escherichia coli
Escherichia coli 0157:H7
esophagitis
ethambutol (ETH)
ethionamide
etravirine
everolimus (EVL)
extended spectrum beta-lactamase (ESBL)
external anogenital warts after transplantation, treatment of
famciclovir
famvir
febrile neutropenia
empiric antifungal therapy in
empiric antimicrobial therapy in
fever
fever early post-liver transplant
fluconazole
flucytosine
fludarabine
flumadine
fluoroquinolone (FQ)
focal brain disease
folinic acid
fomivirsen
fosamprenavir
foscarnet
foscavir
fosfomycin
fumagillin
fungal colonization
lung transplant
Candida
mold
fungal infection
after hematopoietic stem cell transplant
after organ transplant
after transplantation
management of
alemtuzumab (Campath®)
anti-thymocyte globulin (ATG), infections associated with
IL-2R antagonist
rituximab
fungal meningitis
fungal pneumonia
and tracheobronchitis
fungal prophylaxis regimen
for allogeneic hematopoietic stem cell transplant recipients
for autologous hematopoietic stem cell transplant recipients
fungal UTI
Fusarium
ganciclovir (GCV)
resistant CMV infection and disease management
algorithm for
gastrointestinal CMV disease
gentamicin
Giardia
Giardia antigen
Giardia lamblia
giardiasis
glipizide
glyburide
graft pyelonephritis
gram-negative bacilli
gram-positive bacilli
grampositive cocci
Haemophilus influenza
haemophilus influenzae type B vaccine
hand warts after transplantation, treatment of
HBsAg-negative recipient, hepatitis B management in
heart
and lung, infections management in
prophylactic regimens in
transplant recipients, infections management in
hematopoietic stem cell transplant (HSCT)
antimicrobial management of fever and neutronpenia
antimicrobial prophylaxis regimen
for allogeneic HSCT recipients
for autologous HSCT recipients
candidate, pre-transplant infectious disease evaluation of
donor, infectious disease evaluation of
comments
optional donor testing
routine screening, of donors
immunizations after pediatric solid organ transplant
timeline of infections after
hemorrhagic/crusted lesions
hemorrhagic cystitis
hepatic abscess
hepatic artery thrombosis (HAT)
hepatitis
hepatitis A vaccine
hepatitis A virus
hepatitis B core antibody
hepatitis B core antibody-positive donor organ, recipients of
management of
hepatitis B surface antigen (HBsAg)-positive recipients, hepatitis B management in
hepatitis B surface antigen
hepatitis B vaccine
hepatitis B virus (HBV)
alemtuzumab (Campath®)
anti-thymocyte globulin (ATG), infections associated with
IL-2R antagonist
rituximab
hepatitis B virus
hepatitis C antibody
hepatitis C management, in transplant candidates and recipients
hepatitis C virus (HCV)
alemtuzumab (Campath®)
anti-thymocyte globulin (ATG), infections associated with
IL-2R antagonist
residual risk of risk donor categories, usage of
rituximab
hepsera
herpes simplex virus (HSV)
management of
heteroresistant VISA (hVISA)
highly active antiretroviral therapy (HAART)
Histoplasma
Histoplasma antibody
Histoplasma capsulatum
histoplasmosis
HIV antibody
HMG-CoA reductase inhibitors
hMPV infection, prevention and treatment of
HSV-1 antibody
HSV-2 antibody
HTLV, positive
serology, donor with
human herpes virus (HHV) 6, 7 and 8 infections, prevention and treatment of
human immunodeficiency virus (HIV)
management algorithm for
drug–drug interactions and post-transplant management
HIV1 transplant candidates or recipients, antiretroviral drugs in
initial pre-transplant evaluation
patient selection criteria for transplantation
residual risk of risk donor categories, usage of
human immunodeficiency virus (HIV) antibody
human papillomavirus (HPV)
bivalent adjuvanted
external anogenital warts after transplantation, treatment of
hand or plantar (cutaneous) warts after transplantation, treatment of
quadrivalent
vaccine
ideal body weight (IBW)
idoxuridine
IL-2R antagonist, infectious risks associated with
duration of effect
mechanism
imipenem
imiquimod
immune reconstitution
after myeloablative stem cell transplant
immunoglobulin
immunosuppressive drugs
and antimicrobial agents
interactions
mechanisms of action
side-effects
inactivated influenza
inactivated polio vaccine (IPV)
indinavir
infections transmission, from donor to recipient
infectious disease evaluation
of hematopoietic stem cell transplant candidate
of hematopoietic stem cell transplant donor
of organ donor
of organ transplant candidate
influenza
after transplantation, prevention and treatment of
donor with
pandemic virus
seasonal virus
influenza A
influenza B
integrase inhibitor (ralregravir)
interferon-alpha-2b
intestinal microsporidiosis
intestinal transplant recipients, infections management in
intra-abdominal abscess
management of
intranasal influenza (live)
intravascular catheter-related infections
intravenous immunoglobulin (IVIg)
intron A
iodoquinol
isoniazid (INH)
Isospora belli
isosporiasis
itraconazole
ivermectin
lymphocele, infected
meningitis, acute
meningitis, chronic
Mycobacterium tuberculosis infection, treatment of
mycophenolate
Mycophenolate mofetil (MMF)
Mycophenolate sodium (MPS) (myfortic®)
Mycoplasma
Mycoplasma pneumoniae
myeloablative stem cell transplant
immune reconstitution after
Naegleria
Naegleria fowleri
Neisseria meningitidis
nelfinavir
nephropathy
neurocysticercosis
neutrophil engraftment
nevirapine
nifurtimox
nitazoxanide
nitrofurantoin
Nocardia
alemtuzumab (Campath)
Nocardia infections, treatment of
nodules
non-Aspergillus mold colonization
non-live vaccines
for solid organ transplant
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
non-tuberculous Mycobacterium infections, treatment of
nosocomial pneumonia
nosocomial sinusitis
nucleoside reverse transcriptase inhibitors (NRTIs)
nystatin
suspension
OKT3
optional donor testing
oral polio (live) vaccine
oral thrush
oral typhoid (live)
organ donor, infectious disease evaluation of
deceased organ donor
considerations in
presence of infection in
living donor, screening of
optional donor testing
routine screening, of donors
organ transplant
candidate
pre-transplant infectious disease evaluation of
recipients
evaluation and treatment of infectious complications among
pre-emptive therapy of CMV in
prophylaxis regimens in
technical complications with
timeline of infections after
Oseltamivir (Tamiflu®)
Orthoclone OKT3®
oseltamivir
oxacillin
oxamniquine
oxidation-fermentation polymyxin-bacitracin-lactose (OFPBL)
palivizumab
pancreas
prophylactic regimens in
transplant
anastomoses and technical complications
transplant recipients
infections management in
pancreatic abscess
papules
parainfluenzavirus
parasitic infection
after hematopoietic stem cell transplant
after organ transplant
management of, after transplant
paromomycin
parvovirus B19 infection, prevention and treatment of
pediatric solid organ transplant (SOT)
and hematopoietic stem cell transplant (HSCT)
immunizations after
pediatric transplant recipients
antifungal agents for
antiviral agents for
pegasys
Peg-Intron
pegylated interferon (PEG-IFN)
pegylated interferon alpha-2a
pegylated interferon-alpha-2b
penicillin
pentamidine
peramivir
peritoneum and peritoneal space
peritonitis
secondary, management of
peritonitis, secondary
pharyngitis
phenobarbital
phenytoin
pimozide
piperacillin-tazobactam
plantar (cutaneous) warts after transplantation, treatment of
Plasmodium falciparum
non-severe disease
severe/cerebral malaria
Plasmodium malariae
Plasmodium ovale
Plasmodium vivax
pneumococcal conjugate vaccine (PCV)
pneumococcal polysaccharide (PPV23) vaccine
pneumocystis
Pneumocystis carinii pneumonia (PCP)
Pneumocystis jiroveci
for allogeneic hematopoietic stem cell transplant recipients
for autologous hematopoietic stem cell transplant recipients
Pneumocystis jiroveci pneumonia
prophylaxis
therapy
pneumonia
community-acquired
donor with
podofilox
poliovirus (IPV)
polyenes
polyomavirus-associated nephropathy (PyVAN)
and BK polyomavirus
in non-kidney solid organ transplant (SOT) recipients
treatment of
posaconazole
positive syphilis screen, donor with
post-transplant lymphoproliferative disorders (PTLDs), treatment of
praziquantel
prednisone
pre-transplant infectious disease evaluation
of hematopoietic stem cell transplant candidate
of organ transplant candidate
primaquine
primary orolabial/genital (mucocutaneous) infection, management of
probenecid
progressive dementia
proguanil
protease inhibitors
Proteus
proton pump inhibitors
Pseudomonas
Pseudomonas aeruginosa
Pseudomonas cepacia (PC) agar
purified protein derivative (PPD) testing
pyelonephritis
pyrazinamide (PZA)
pyridoxine
pyrimethamine
QTc prolonging medications
quinidine
quinidine gluconate
quinine
quinine sulfate
quinolone
quinupristin-dalfopristin
rabbit anti-thymocyte globulin
rabies vaccine
rapid plasma reagin
reactivated orolabial/genital (mucocutaneous) infection, management of
recurrent UTI
respiratory syncytial virus (RSV)
after transplantation, prevention and treatment of
infections, prevention and treatment of
retinitis
rhinoviruses
infections, prevention and treatment of
ribavirin
Rickettsia
rifabutin
rifampin (RIF)
rifampin/rifabutin
right lobe living donor liver transplant
anastomoses and technical complications
rimantadine
ritonavir
rituximab
infectious risks associated with
Rocky Mountain Spotted Fever
rotavirus
routine screening, of donors
S. typhi Ty21a (Vivotif)
safe living strategies, for transplant patients
animal contact
food safety
infections transmitted by direct contact
respiratory infections
safe sexual practices
travel safety
water safety
Salmonella
Salmonella typhi (Typhim Vi) vaccine
saquinavir
saturated solution of potassium iodide (SSKI)
Scedosporium
Schistosoma hematobium
Schistosoma intercalatum
Schistosoma japonicum
Schistosoma mansoni
Schistosoma mekongi
septic shock syndrome
serology and nucleic acid testing
window period length for
estimates of
Serratia marcescens
serum galactomannan
severe acute respiratory syndrome coronavirus (SARSCoV)
prevention and treatment of
severe CMV disease
sexually transmitted diseases
simvastatin
sinusitis
community-acquired
nosocomial
sirolimus (SRL)
skin and soft tissue infection
cellulitis
hemorrhagic/crusted lesions
nodules
papules
skin necrosis
surgical wound infection
ulcers
vesicles
small bowel, prophylactic regimens in
small particle aerosol generator (SPAG-2)
smallpox vaccine (live) vaccine
smallpox vaccine
solid organ transplant (SOT) recipients
adult vaccination schedule after
live vaccines
non-live vaccines
vaccinations prior to travel
cytomegalovirus (CMV) disease in
prevention
treatment
immunizations after pediatric and HSCT
screening for BKV replication and PyVAN in non-kidney
sotalol
Sporothrix
Staphylococcus
Staphylococcus aureus
St John’s Wort
streptococcal pharyngitis
streptococci
Streptococcus pneumoniae
Streptococcus pyogenes
Streptococcus spp.
streptomycin (SM)
Strongyloides
donor with
Strongyloides antibody
Strongyloides stercoralis
strongyloidiasis
subacute meningitis
sulbactam
sulfadiazine
sulfadoxine/pyrimethamine (Fansidar®)
sulfadoxine/pyrimethamine
sulfamethoxazole (SMX)
suppressive therapy, reactivation/chronic
prevention of
surgical site infection, management of
surgical wound infection, of skin and soft tissue infection
syphilis
tacrolimus (Tac) (Prograf®)
Taenia solium
T-cell engraftment
telbivudine
tenofovir
terbinafine
tetracycline
thioridazine
thrombectomy
tigecycline (TIG)
timeline of infections
after hematopoietic stem cell transplant
after organ transplant
tinidazole
tipranavir
tissue-invasive CMV disease
tobramycin
tomatitis
tonsillitis
Toxoplasma
Toxoplasma antibody
Toxoplasma gondii
Toxoplasma IgG antibody
Toxoplasma pneumonia
toxoplasmosis
tracheobronchitis
and fungal pneumonia
travel-related vaccinations, for transplant travelers
triazolam
triazoles
trifluridine (viroptic)
trifluridine
trimethoprim-sulfamethoxazole (TMP-SMX)
trivalent inactivated influenza vaccine
Trypanosoma
Trypanosoma cruzi
Trypanosoma cruzi antibody
trypanosomiasis
tuberculosis
donor with
treatment and prevention
tuberculosis, active
tuberculosis, latent
post-transplant recipient with
pre-transplant candidate with
tuberculosis, of donor
potential scenarios and management
typhoid Vi polysaccharide (inactivated) vaccine
ulcers
ureteral stenosis
ureteral ulceration
urinary tract infection (UTI)
donor with
management of
urinoma, infected
vaccinations prior to travel
valacyclovir (Valtrex)
valganciclovir (Valcyte)
valganciclovir
vancomycin
vancomycin-intermediate Staphylococcus aureus (VISA)
vancomycin-resistant Enterococci (VRE)
vancomycin-resistant Staphylococcus aureus
varicella (chickenpox) (live) vaccine
varicella vaccine
varicella zoster (shingles) (live) vaccine
varicella zoster (shingles) vaccine
varicella zoster vaccine
varicella zoster virus (VZV)
management of
VariZig
vesicles
Vibrio sp.
vidarabine
video-assisted thoracoscopic surgery (VATS)
viral infection
after hematopoietic stem cell transplant
after organ transplant
viral prophylaxis regimen
for allogeneic HSCT recipients
for autologous HSCT recipients
voriconazole
wafarin
window period
length for serology and nucleic acid testing
wound infection
in heart–lung transplant recipients
in heart transplant recipients
in kidney transplant recipients
in liver transplant recipients
in lung transplant recipients
in pancreas transplant recipients
yellow fever (live) vaccine
yellow fever vaccine
Yersinia
zanamavir (Relenza)
zidovudine
Zygomyces infections
zygomycetes
Zygomycetes sp.